HC Wainwright Cuts GH Research (NASDAQ:GHRS) Price Target to $35.00

GH Research (NASDAQ:GHRS) had its price target lowered by stock analysts at HC Wainwright from $40.00 to $35.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 159.55% from the company’s current price.

A number of other research firms also recently issued reports on GHRS. Wall Street Zen downgraded shares of GH Research from a “hold” rating to a “sell” rating in a research report on Saturday. Zacks Research cut GH Research from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 13th. Needham & Company LLC started coverage on GH Research in a research report on Monday, October 13th. They set a “buy” rating and a $19.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of GH Research in a report on Wednesday, October 8th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.75.

GH Research Stock Performance

GH Research stock traded down $0.02 during midday trading on Monday, reaching $13.49. The company’s stock had a trading volume of 63,062 shares, compared to its average volume of 323,764. The firm has a market capitalization of $701.62 million, a PE ratio of -18.22 and a beta of 0.97. GH Research has a fifty-two week low of $6.72 and a fifty-two week high of $20.50. The stock’s 50 day simple moving average is $13.45 and its 200 day simple moving average is $13.05.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.23). Equities analysts predict that GH Research will post -0.8 earnings per share for the current year.

Institutional Investors Weigh In On GH Research

A number of hedge funds and other institutional investors have recently modified their holdings of GHRS. Osaic Holdings Inc. boosted its position in GH Research by 63.6% during the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after acquiring an additional 2,400 shares during the last quarter. JPMorgan Chase & Co. purchased a new position in shares of GH Research during the 2nd quarter worth $79,000. Virtus Investment Advisers LLC acquired a new stake in shares of GH Research during the second quarter worth $89,000. XTX Topco Ltd acquired a new stake in shares of GH Research during the first quarter worth $169,000. Finally, BNP Paribas Financial Markets lifted its position in GH Research by 165.4% during the second quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock worth $207,000 after buying an additional 10,600 shares during the period. 56.90% of the stock is currently owned by hedge funds and other institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).